BBB-Targeted GAA Gene Therapy for CNS Pompe Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery approaches for therapeutic proteins to the central nervous system (CNS) face challenges such as instability in blood circulation, undesirable biodistribution, and inefficient targeting due to the blood-brain barrier, particularly for lysosomal storage diseases, where existing methods fail to provide consistent and effective enzyme replacement therapy.
Innovation Solution
A method involving a nucleotide composition encoding a therapeutic protein conjugated to a cell surface receptor-binding protein, delivered via a liver-targeted gene therapy vector, which achieves consistent blood levels and efficient delivery to the CNS using receptor-binding proteins like antibodies or antigen-binding fragments, specifically targeting internalization receptors like CD63 or TfR to facilitate entry into the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If nanocarriers are used to deliver therapeutic proteins to the CNS, then delivery capability is improved, but stability in blood circulation and biodistribution become undesirable
Solution Approach 1:
The patent uses an intermediary protein (such as transferrin receptor-binding protein or CD63-binding protein) as a mediator between the therapeutic protein and the BBB. This intermediary binds to receptors on the BBB surface and facilitates transcytosis, allowing the therapeutic protein to cross the barrier without requiring the therapeutic protein itself to be stable in circulation or have ideal biodistribution properties.
Solution Approach 2:
The delivery system is segmented into separate functional components: the therapeutic protein (which may be unstable or have poor biodistribution) and the intermediary binding protein (which provides BBB targeting and transcytosis capability). This segmentation allows each component to be optimized independently for its specific function.
2Device complexity
If conventional delivery methods are used for CNS diseases, then simplicity is maintained, but targeting efficiency is compromised due to BBB integrity and neuroinflammatory conditions
Solution Approach 1:
The patent changes the binding specificity parameter of the intermediary protein to match different BBB receptor types (such as transferrin receptor, CD63, or other internalization receptors). This allows the system to adapt to different BBB states and neuroinflammatory conditions by selecting or modifying the binding protein to match the current receptor expression profile in the target tissue.
3Object-generated harmful factors
If therapeutic proteins are delivered via DNA expression in the liver, then immunogenicity is reduced, but efficient delivery to the CNS is not achieved
Solution Approach 1:
The patent introduces an intermediary protein that binds to BBB receptors and mediates the transport of the therapeutic protein from the liver (where it is produced via DNA expression) to the CNS. This intermediary acts as a bridge, allowing the liver-produced protein to reach the brain without requiring direct CNS injection or having ideal CNS tropic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a therapeutically effective delivery of therapeutic proteins, such as lysosomal enzymes, to the CNS, maintaining consistent blood levels and improving tissue biodistribution, thereby addressing the limitations of existing methods for treating CNS disorders and lysosomal storage diseases.
Implementation Method 1
the CSR-BP is an antigen-binding protein that binds to an internalization receptor. In one embodiment, the internalization receptor is a cell-surface molecule that is endocytosed and trafficked to the lysosome.
Implementation Method 2
Multidomain therapeutic proteins can be delivered to the liver via a gene therapy vector harboring the coding sequence of the therapeutic protein and binding protein complex
Data Source
AI summary
Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases, are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein, e.g., anti-TfRCscfv:GAA, that crosses the blood brain barrier (BBB) are provided.